A seasoned Pfizer rare disease executive who pivoted to entrepreneurship to co-found a gene therapy company focused on genetic cardiovascular and CNS disorders.
Primeros años: Townsend built his foundational career in the corporate pharmaceutical world, gaining extensive experience in strategy and operations before venturing into the biotech startup ecosystem.
Primer gran salto: His tenure as President of Pfizer Rare Disease (North America) provided the strategic and operational platform that enabled him to transition into founding Lexeo.
Camino al CEO: Townsend co-founded Lexeo Therapeutics in 2020 alongside Dr. Ronald Crystal. Drawing on his years of corporate leadership and international rare disease experience, he led the company through its clinical evolution and onto the public markets in 2023.
Visión original: To leverage AAV-based genetic medicine to treat genetically defined cardiovascular and central nervous system (CNS) diseases, an area with high unmet medical need.
R. Nolan Townsend's path to CEO was characterized by a deliberate transition from big pharma strategy to biotech leadership. After spending over a decade at Pfizer, where he ultimately led the Rare Disease business for North America, Townsend applied his expertise in drug development and commercial strategy to co-found Lexeo Therapeutics. His early career gave him a deep understanding of the complexities of rare disease drug development, which became the cornerstone of Lexeo's R&D mission. Since 2020, he has steered the company from a startup through early clinical trials and an IPO, focusing on a pipeline of gene therapies that target specific, often underserved, patient populations.
founderbiotech entrepreneurformer big pharmagene therapy
